CIDID Polio Modelers at The University of Michigan Epidemiology: Jim Koopman, Marisa Eisenberg, Joe Eisenberg, Christopher Henry, Xinyu Zhang Statistics:

Slides:



Advertisements
Similar presentations
Weekly Polio Update Nigeria March 7, As at March 7, 2014 Nigeria has:- 1 confirmed WPV1 in 1 State compared to 4 cases in 4 States for the same.
Advertisements

Module 1 Introduction to the polio endgame rationale and IPV vaccine
Polio Eradication Dr Marvin Hsiao Division of Medical Virology NHLS/UCT/Groote Schuur Hospital.
Poliomyelitis Surveillance in Ireland 4 th April, 2014.
IPV IPV Rapidly produces high level of protective antibodies No risk of vaccine associated illness No interference from other enteroviruses. I.P.V. produces.
بسم الله الرحمن الرحيم. IRAN Vaccination policy for post eradication phase Presented by : A. R.ESTEGHAMATI, MD IRAN EPI Manager.
Global Action Plan for Laboratory Containment of Wild Polioviruses
Respiratory Bacteria Vaccines: Model Analyses for Vaccine and Vaccine Trial Design Jim Koopman MD MPH Ximin Lin MD MPH Tom Riggs MD MPH Dept. of Epidemiology.
Poliomyelitis First described by Michael Underwood in 1789 First outbreak described in U.S. in ,000 paralytic cases reported in the U. S. in 1952.
Economics of Research and Surveillance: Value of Information David Hutton.
WHO RAP Team: Perspective and Update WORKSHOP ON ANALYZING THE POLIO ERADICATION ENDGAME, Seattle, 1-2 July 2015.
Completing The Endgame Global Polio Eradication
Polio eradication programme in India – Progress, Response and Issues for action Dr Ajay Khera Deputy Commissioner Ministry of Health & FW, Govt. of India.
The Evolving 'Polio Endgame' Strategy
Conclusions & Recommendations 24 th IEAG March 2012.
Polio Update Pre Tender Meeting 11 th December 2008 UNICEF Supply Division.
Polio End-game: What are the implications on polio vaccination policy? Dr Raju Shah.
The Challenge: How to Accelerate Eradication and the 'Endgame'?
Highlights of New WPV Cases 34 new cases in 5 countries 14 cases (14 W3) but no new district in India Most recent date of onset 03 Oct 1 case (W1) but.
Data in WHO HQ as of 09 October 2012 Highlights of New Wild Poliovirus Cases The boundaries and names shown and the designations used in the maps in this.
Polio and Polio Vaccine
Vaccine-Derived Poliovirus Infections Minnesota, 2005 Jim Alexander & Jane Seward National Vaccine Advisory Committee Washington, DC February 8, 2006.
By Archana Bhasin. Poliomyelitis is a viral disease that can affect nerves and can lead to partial or full paralysis.
Infectious Disease Epidemiology, Module I Introduction.
Polio Eradication and End Game Strategy
Measles elimination Dr. As’ad Ramlawi Palestine..
Vaccine-Derived Poliovirus Infections in an Amish Population Minnesota, 2005 Harry F. Hull, M.D. State Epidemiologist Minnesota Department of Health.
Curriculum Development Infectious Diseases Assumptions Students may not have M.D. Goal To enable students to identify problems, investigate, and control.
Introduction for Basic Epidemiological Analysis for Surveillance Data National Center for Immunization & Respiratory Diseases Influenza Division.
Sustaining Polio Eradication IEAG March 2012 The experience of polio-free countries with importations of WPV: Implications for India.
Polio Endgame Strategy in India Considerations and Way Forward WHO-India, NPSP 15 March 2012.
1 Polio Strategic Plan India Expert Advisory Group July 2011 Impact & prospects at the half-way point.
Epidemiology of Poliomyelitis Ashry Gad Mohamed MBchB, MPH, DrPH Prof. of Epidemiology Medical College, KSU.
Data and Models for Inferring Expected Effects of PrEP Programs Jim Koopman; Erik Volz; Ethan Romero- Severson; Ed Ionides, Shah Jamal Alam University.
Data in WHO HQ as of 17 Apr 2012 Highlights of New Wild Poliovirus Cases The boundaries and names shown and the designations used in the maps in this document.
Global Polio Eradication Initiative The 'Intensified Effort' 18 May 2008.
Responding To An Infection Transmission Emergency Jim Koopman MD MPH University of Michigan Center for the Study of Complex Systems & Dept. of Epidemiology.
National Immunization Program (NIP)/Advisory Committee on Immunization Practices (ACIP) Report Stephen L. Cochi, MD, MPH Acting Director, National Immunization.
American Academy of Pediatrics, Committee on Infectious Diseases. Policy Updated Recommendations on the Use of Meningococcal Vaccines Pediatrics. doi:
February 2015 An introduction to the switch from trivalent to bivalent oral polio vaccines 1.
Poliomyelitis. Instructional Objectives: At the end of the lecture the student would be able to: 1-Demonstrate the main clinical characteristics of poliomyelitis.
The polio endgame and silent circulation: some related research.
Module 1 Introduction to the polio endgame rationale and IPV vaccine
Approaches to modeling, parameter estimation, and policy guidance during the endgame Guillaume Chabot-Couture Philip Eckhoff Mike Famulare Hao Hu Hil Lyons.
Polio and Polio Vaccine Epidemiology and Prevention of Vaccine- Preventable Diseases National Immunization Program Centers for Disease Control and Prevention.
Rubella Surveillance and Control in Low-Resource Settings: Limitations, Biases, and Potential for Strengthening Amy Winter, PhD Candidate, Princeton University.
Chapter 1: Epidemiology and Its Progress
Data quality for polio eradication: Accuracy & reliability
Perspective and Update
Global Polio Eradication: Current Status, Challenges and Future Directions Steven Wassilak, MD Centers for Disease Control and Prevention, Atlanta APHA.
Introduction to the polio endgame rationale and IPV vaccine
Performance of AFP surveillance, 2014
Vaccine-Derived Poliovirus Outbreak Minnesota, 2005
The Polio Eradication and Endgame Strategic Plan
Acute Flaccid Paralysis Surveillance in Ireland
06/12/2018 Highlights of New Wild Poliovirus and cVDPV Positives Reported Globally this Week 1Environmental sampling, contacts of AFP cases, community.
Controlled Human Infection Models
Nigeria Update Epidemiology of Wild Poliovirus
15/01/2019 Highlights of New Wild Poliovirus and cVDPV Positives Reported Globally this Week The boundaries and names shown and the designations used in.
Preparing for the Switch
24/02/2019 Highlights of New Wild Poliovirus and cVDPV Positives Reported Globally this Week 1Environmental sampling, contacts of AFP cases, community.
Onset of most recent WPV1 Case Number of WPV infected districts
08/04/2019 Highlights of New Wild Poliovirus and cVDPV Positives Reported Globally this Week 1Environmental sampling, contacts of AFP cases, community.
No new positives this week
05/04/2019 Highlights of New Wild Poliovirus and cVDPV Positives Reported Globally this Week 1Environmental sampling, contacts of AFP cases, community.
08/04/2019 Highlights of New Wild Poliovirus and cVDPV Positives Reported Globally this Week The boundaries and names shown and the designations used in.
16/05/2019 Highlights of New Wild Poliovirus and cVDPV Positives Reported Globally this Week 1Environmental sampling, contacts of AFP cases, community.
27/08/2019 Highlights of New Wild Poliovirus and cVDPV Positives Reported Globally this Week 1Environmental sampling, contacts of AFP cases, community.
Nili Karako Eyal, School of Law, College of Management, Israel
Fig. 4 Age-specific immunity and transmission dynamics under two- and three-dose vaccine schedules. Age-specific immunity and transmission dynamics under.
Presentation transcript:

CIDID Polio Modelers at The University of Michigan Epidemiology: Jim Koopman, Marisa Eisenberg, Joe Eisenberg, Christopher Henry, Xinyu Zhang Statistics: Edward Ionides, JoonHa Park HMP: David Hutton

Important Endgame Modeling Issues Insure there is no silent circulation when OPV is stopped –Persistent cVDPV2, WPV1, WPV3 1.Model reinfection transmission dynamics accurately enough to insure endgame policies don’t permit silent circulation Infer whether vaccinating adults is needed to insure silent circulation ends before global OPV cessation Modern complex system analyses of data covering last 15 years 2.Investigate re-emergence of transmission after OPV is stopped with intensive asymptomatic infection detection, sequencing, and serology across all age groups Infer whether “whack-a-mole” policy will work or if booster IPV or OPV vaccinations are needed in specific age groups

What needs to change Better complex system science that elucidates how program decisions are affected by –waning immunity dynamics, –dose response effects on transmission, –transmission routes (direct, fomite, water) More effective interaction between modeling groups –Building a common understanding of what needs to be done More scientists involved in modeling complex systems! More accessible data over longer times from more areas –AFP surveillance, Environmental surveillance, Virus sequences, Vaccination administration, Demographic data